

FIG. 1




FIG. 2




FIG. 3




FIG. 4





FIG. 5









FIG. 7







FIG. 9

FIG. 10








FIG. 12




FIG. 13




FIG. 14

FIG. 15




FIG. 16




FIG. 17




FIG. 18

FIG. 19




FIG. 21

FIG. 22




FIG. 23

FIG. 24

FIG. 25

Veritas Internet Content Editor	Select a disease
(TRIAL ID:1835) Inhaled Doxorubicin in Treating Patients With Primary Lung Cancer or Lung Metastases [ Question3: ? Question4: ? Question5: ? Question6: ? Question6: ? Question6: ? Question7: ? Question8: Ignore Question9: ? Question10: ? ] Show Trial? YES	go to the Lung Cancer front page (10: ?) 2508
(TRIAL ID:1842) Vaccine Therapy Plus QS21 in Treating Patients With Small Cell Lung Cancer That Has Responded to Initial Therapy [ Question3: Yes Question4: ? Question5: ? Question6: No Question7: Ignore Question8: Ignore Question9: ? Question10: ? ] Percentage: 4 / 6: 67% Show Trial? NO	sponded to Initial Therapy Justion10: ? ]
(TRIAL ID:1914) Marimastat Following Chemotherapy in Treating Patients With Small Cell Lung Cancer [ Question3: Yes Question4: ? Question5: ? Question7: ? Question8: Ignore Question9: ? Question10: ? ] Percentage: 4/4: 100% Show Trial? YES	10: ? ]
(TRIAL ID:1936)   Question3: Yes Question4: ? Question5: ? Question6: ? Question7: Ignore Question8: Ignore Question9: ? Question10: ? ] Percentage: 4/5: 80% Show Trial? YES	stion10: ? ]
(TRIAL ID:1949)       Depsipeptide to Treat Lung Cancer         [ Question3: ? Question4: ? Question5: ? Question6: Yes Question7: ? Question8: Ignore Question9: ? Question10: ? ]         Percentage: 2 / 4: 50%         Show Trial? YES	10: 2]
(TRIAL ID:1953) Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors [ Question3: Yes Question4: ? Question5: ? Question6: ? Question7: Ignore Question8: Ignore Question9: ? Question10: Percentage: 4 / 5: 80% Show Trial? YES	<u>mors</u> stion10: ? ]
(TRIA) IN-1956). Combination Chemotherany Plus Perinheral Stem Cell Transnlantation in Treating Patients With Metastatic Cancer	S With Motactatic Cancer

FIG. 25A




FIG. 26




FIG. 27

FIG. 28




FIG. 29

